Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 6, 2022
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
[ Thu, Jan 06th 2022
] - WOPRAI
Matthew Harrison Downgraded (AVIR) to Sell and Decreased Target to $7 on, Jan 6th, 2022
Matthew Harrison of Morgan Stanley, Downgraded "Atea Pharmaceuticals, Inc." (AVIR) to Sell and Decreased Target from $14 to $7 on, Jan 6th, 2022.
Matthew has made no other calls on AVIR in the last 4 months.
There are 2 other peers that have a rating on AVIR. Out of the 2 peers that are also analyzing AVIR, all agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Roanna Ruiz of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $11 on, Thursday, November 18th, 2021
- Eric Joseph of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $16 on, Wednesday, October 20th, 2021
